{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:17:08Z","timestamp":1788675428607,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"DOI":"10.1007\/s10689-025-00455-x","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T08:31:32Z","timestamp":1742718692000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Azacitidine and venetoclax for the treatment of AML arising from an underlying telomere biology disorder"],"prefix":"10.1007","volume":"24","author":[{"given":"Arjun","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Velsher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2844-2256","authenticated-orcid":false,"given":"James A.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"key":"455_CR1","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1080\/17474086.2019.1662720","volume":"12","author":"MR Niewisch","year":"2019","unstructured":"Niewisch MR, Savage SA (2019) An update on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol 12:1037\u20131052","journal-title":"Expert Rev Hematol"},{"key":"455_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3324\/haematol.2017.178111","volume":"103","author":"BP Alter","year":"2018","unstructured":"Alter BP, Giri N, Savage SA, Rosenberg PS (2018) Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up. Haematologica 103:30\u201339","journal-title":"Haematologica"},{"key":"455_CR3","unstructured":"Agarwal S, Savage SA, Stevens KB (2022) Telomere biology disorders diagnosis and management guidelines. Team Telomere. https:\/\/teamtelomere.org\/diagnosis-management-guidelines\/"},{"key":"455_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/hematolrep14040042","volume":"14","author":"H Ramos","year":"2022","unstructured":"Ramos H, Aly MM, Balasubramanian SK (2022) Late presentation of dyskeratosis congenita: germline predisposition to adult-onset secondary acute myeloid leukemia. Hematol Rep 14:294\u2013299","journal-title":"Hematol Rep"},{"key":"455_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629","journal-title":"N Engl J Med"},{"key":"455_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-020-00386-z","volume":"10","author":"A Ferrer","year":"2020","unstructured":"Ferrer A, Mangaonkar AA, Stroik S, Zimmermann MT, Sigafoos AN, Kamath PS et al (2020) Functional validation of TERT and TERC variants of uncertain significance in patients with short telomere syndromes. Blood Cancer J 10:1\u20135","journal-title":"Blood Cancer J"},{"key":"455_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405\u2013424","journal-title":"Genet Med"},{"key":"455_CR8","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/jcp.31034","volume":"238","author":"NH Zade","year":"2023","unstructured":"Zade NH, Khattar E (2023) POT1 mutations cause differential effects on telomere length leading to opposing disease phenotypes. J Cell Physiol 238:1237\u20131255","journal-title":"J Cell Physiol"},{"key":"455_CR9","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1101\/gad.276873.115","volume":"30","author":"H Takai","year":"2016","unstructured":"Takai H, Jenkinson E, Kabir S, Babul-Hirji R, Najm-Tehrani N, Chitayat DA et al (2016) A POT1 mutation implicates defective telomere end fill-in and telomere truncations in Coats plus. Genes Dev 30:812\u2013826","journal-title":"Genes Dev"},{"key":"455_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41576-022-00527-z","volume":"24","author":"P Revy","year":"2023","unstructured":"Revy P, Kannengiesser C, Bertuch AA (2023) Genetics of human telomere biology disorders. Nat Rev Genet 24:86\u2013108","journal-title":"Nat Rev Genet"},{"key":"455_CR11","doi-asserted-by":"publisher","first-page":"e147598","DOI":"10.1172\/JCI147598","volume":"131","author":"KE Schratz","year":"2021","unstructured":"Schratz KE, Gaysinskaya V, Cosner ZL, DeBoy EA, Xiang Z, Kasch-Semenza L et al (2021) Somatic reversion impacts myelodysplastic syndromes and acute myeloid leukemia evolution in the short telomere disorders. J Clin Invest 131:e147598","journal-title":"J Clin Invest"},{"key":"455_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/bjh.15495","volume":"183","author":"F Fioredda","year":"2018","unstructured":"Fioredda F, Iacobelli S, Korthof ET, Knol C, van Biezen A, Bresters D et al (2018) Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. Br J Haematol 183:110\u2013118","journal-title":"Br J Haematol"},{"key":"455_CR13","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/16078454.2022.2120305","volume":"27","author":"J Geng","year":"2022","unstructured":"Geng J, Zhao M, Li Q (2022) Severe immunochemotherapy-induced toxicities in a patient with dyskeratosis congenita and literature review. Hematology 27:1041\u20131045","journal-title":"Hematology"},{"key":"455_CR14","doi-asserted-by":"publisher","first-page":"e2200693","DOI":"10.1200\/PO.22.00693","volume":"7","author":"J Ma","year":"2023","unstructured":"Ma J, Morimoto K, Pulsipher MA, Parekh C (2023) Venetoclax and azacitidine in the treatment of NPM1-mutated donor cell-derived leukemia in a patient with fanconi anemia: case report and literature review. JCO Precis Oncol 7:e2200693","journal-title":"JCO Precis Oncol"},{"key":"455_CR15","unstructured":"Place AE (2025) A phase I study of venetoclax in combination with cytotoxic chemotherapy, including calaspargase pegol, for children, adolescents and young adults with high-risk hematologic malignancies. clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05292664. Accessed 2 Feb 2025"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00455-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-025-00455-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00455-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T04:57:43Z","timestamp":1750913863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-025-00455-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["455"],"URL":"https:\/\/doi.org\/10.1007\/s10689-025-00455-x","relation":{},"ISSN":["1573-7292"],"issn-type":[{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"14 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This patient provided informed consent for publication of this material satisfying the requirements of the Sunnybrook Health Sciences Research Ethics Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"31"}}